Skip to main content

Authors’ response to Ashley Roberts’ letter to the editor on aspartame and cancer

The Original Article was published on 21 September 2021

Ashley Roberts, a consultant to the Calorie Control Council, a food-industry trade group that promotes the use of aspartame and other artificial sweeteners, ( makes several incorrect and unsubstantiated claims in his response to our recent commentary, “Aspartame and Cancer – New Evidence for Causation” [1].

Our commentary discussed the significance of a report by Tibaldi et al. (2020) who reexamined lesions from Ramazzini Institute (RI) studies of rodents exposed to aspartame [2]. Those RI studies had reported that aspartame causes dose-related increases in malignant lesions in multiple organs in rats and mice [3,4,5]. The studies reported additionally that prenatal aspartame exposures caused increased cancers in offspring at lower doses than in adults [4], a finding of serious concern for public health given the extensive consumption of low-calorie, aspartame-sweetened beverages by pregnant women. The goal of the study by Tibaldi et al. was to evaluate the accuracy of the RI’s diagnoses of malignancy.

Tibaldi et al.’s reevaluation included both immunohistochemical and morphological examinations of the rodent lesions. The premise underlying immunohistochemical analysis is that all cells in a malignant lesion are expected to be immunohistochemically identical - i.e., monoclonal – because they are all the direct descendants of a single transformed cell [6, 7]. By contrast, the inflammatory lymphocytes that respond to an infection are of diverse cellular origin. They are therefore not immunohistochemically identical, and instead are polyclonal. Tibaldi et al’s immunohistochemical analysis employed a battery of nine markers: Ki67, CD3, PAX5, CD20, CD68, TdT, CD45, CD14 and CD33.

Tibaldi et al confirmed that 72 of the 78 lesions originally diagnosed by RI as malignant were, in fact, monoclonal. Tibaldi et al. thus confirmed the original RI diagnoses of malignancy in 92.3% of the aspartame-exposed rodents [2].

Roberts’ critique is based on his review of the histological slides presented by Tibaldi et al. and on the unsubstantiated and previously refuted [8, 9] claim that there was infection in the RI laboratories that caused inflammatory lesions in the experimental animals. He ignores Tibaldi et al.’s immunohistochemical findings and does not attempt to rebut them.

Roberts also fails to acknowledge, rebut or offer any alternative explanation for the dose-response relationship between aspartame dose and cancer incidence that was clearly evident in the RI studies and was confirmed by Tibaldi et al. Increasing aspartame exposures were associated with statistically significant increases in incidence of all hematolymphatic malignancies (p = 0.006), including both lymphomas (p = 0.032) and leukemias (p = 0.031) [2]. Infection would seem an unlikely explanation for such a trend.

Likewise, Roberts fails to acknowledge, rebut or explain away the RI finding that prenatal exposures to aspartame caused increased malignancies in offspring at lower doses than in adults [4]. Again, Infection would seem an unlikely explanation for this finding.

In summary, we find Robert’s critique to be flawed and unconvincing. We therefore reiterate our conclusion that national and international public health agencies need to follow the example of the International Agency for Research on Cancer (IARC) [9] and take careful notice of these new data on the carcinogenicity of aspartame [2]. These agencies need to pay particular heed to the potential of lower-dose aspartame exposures during pregnancy to cause increased incidence of leukemia and lymphoma in offspring [4].

Facile dismissals of the carcinogenicity of aspartame put forth by vested interests can no longer be sustained. Such unsubstantiated claims can impede public health interventions and can lead to unnecessary cancers, including childhood cancers and premature deaths.

Availability of data and materials

Not applicable.


  1. 1.

    Landrigan PJ, Straif K. Aspartame and cancer – new evidence causation. Environ Health. 2021;20(1):42.

    CAS  Article  Google Scholar 

  2. 2.

    Tibaldi E, Gnudi F, Panzacchi S, Mandrioli D, Vornoli A, Manservigi M, Sgargi D, Falcioni L, Bua L, Belpoggi F. Identification of aspartame-induced haematopoietic and lymphoid tumours in rats after lifetime treatment. Acta Histochem. 2020;122:15148.

    CAS  Article  Google Scholar 

  3. 3.

    Belpoggi F, Soffritti M, Padovani M, Degli Esposti D, Lauriola M, Minardi F. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed. Ann NY Acad Sci. 2006;1076:559–77.

    CAS  Article  Google Scholar 

  4. 4.

    Soffritti M, Belpoggi F, Tibaldi E, Degli Esposti D, Lauriola M. Life-span exposure to low doses of aspartame beginning during prenatal life increases Cancer effects in rats. Environ Health Perspect. 2007;115(9):1293–7.

    CAS  Article  Google Scholar 

  5. 5.

    Soffritti M, Belpoggi F, Manservigi M, Tibaldi E, Lauriola M, Falcioni L, Bua L. Aspartame administered in feed, beginning prenatally through life span, induces cancers of the liver and lung in male Swiss mice. Am J Ind Med. 2010;53:1197–206.

    CAS  Article  Google Scholar 

  6. 6.

    van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocol for detection of clonal immunoglobulin and T cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98–3936. Leukaemia. 2003;17(12):2257–317.

    Article  Google Scholar 

  7. 7.

    Gift JS, Caldwell JC, Jinot J, Evans MV, Cote I, Vandenberg JJ. Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini institute. Environ Health Perspect. 2013;121:1253–63.

    CAS  Article  Google Scholar 

  8. 8.

    Caldwell JC, Jinot J, DeVoney D, Gift JS. Evaluation of evidence for infection as a mode of action for induction of rat lymphoma. Environ Mol Mutagen. 2008;49(2):155–64.

    CAS  Article  Google Scholar 

  9. 9.

    IARC (International Agency for Research on Cancer), IARC Monographs Priorities Group. Advisory Group. Recommendations on priorities for the IARC Monographs. Lancet Oncol. 2019;20(6):763–4.

    Article  Google Scholar 

Download references


The authors acknowledge the invaluable contributions to cancer biology and prevention of Drs. Cesare Maltoni, Morando Soffritti and Fiorella Belpoggi of the Ramazzini Institute.



Author information




Both authors contributed to the conceptualization, writing and editing of the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Philip J. Landrigan.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

Drs. Landrigan and straif are both unpaid members of the International Scientific Advisory Board of the Ramazzini Institute.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Landrigan, P.J., Straif, K. Authors’ response to Ashley Roberts’ letter to the editor on aspartame and cancer. Environ Health 20, 107 (2021).

Download citation